Skye Bioscience, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
SKYE Nasdaq 2834 skyebioscience.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Skye Bioscience, Inc.

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025 - Mar 14th, 2025 11:00 am
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Feb 27th, 2025 11:00 pm
Skye Bioscience to Participate in SXSW Session on Obesity - Feb 24th, 2025 12:00 pm
We're Hopeful That Skye Bioscience (NASDAQ:SKYE) Will Use Its Cash Wisely - Feb 22nd, 2025 12:15 pm
Skye Bioscience to Present at TD Cowen Health Care Conference - Feb 20th, 2025 12:00 pm
Skye Bioscience Announces Participation in February Conferences - Feb 4th, 2025 12:00 pm
Skye Bioscience Provides 2025 Look Ahead and Year in Review - Jan 13th, 2025 12:00 pm
Skye Bioscience to Present at J.P. Morgan Healthcare Conference - Dec 19th, 2024 12:00 pm
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences - Nov 18th, 2024 12:00 pm
Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond - Nov 15th, 2024 12:45 pm
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor - Nov 14th, 2024 12:00 pm
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights - Nov 7th, 2024 9:01 pm
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model - Nov 4th, 2024 12:00 pm
Skye Bioscience to Announce Third Quarter 2024 Results - Nov 1st, 2024 11:00 am
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board - Oct 29th, 2024 11:00 am
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences - Oct 21st, 2024 11:00 am
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan - Sep 23rd, 2024 11:00 am
Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer - Sep 3rd, 2024 11:00 am
Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences - Aug 26th, 2024 11:00 am
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity - Aug 22nd, 2024 11:00 am